Open AccessDelamanid is a new anti-tuberculosis drug: use, limitations, and prospects
Author(s) -
В. Н. Зимина,
И. Б. Викторова
Publication year - 2021
Publication title -
tuberkulez i bolezni lëgkih/tuberkulëz i bolezni lëgkih
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.226
H-Index - 12
eISSN - 2542-1506
pISSN - 2075-1230
DOI - 10.21292/2075-1230-2021-99-2-58-66
Subject(s) - tuberculosis , drug , medicine , intensive care medicine , human immunodeficiency virus (hiv) , pharmacokinetics , drug resistant tuberculosis , pharmacology , mycobacterium tuberculosis , virology , pathology
The review analyses 61 publications on the use of delamanid, a new drug for the treatment of drug resistant tuberculosis. It presents information about pharmacokinetic parameters, efficacy and safety, as well as the place of delamanid in the combination therapy of multiple drug resistant tuberculosis. It tells about specific parameters of delamanid use in children and HIV patients.